Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines : Epidemiology

Secondary Logo

Journal Logo

Infectious Diseases

Theoretical Framework for Retrospective Studies of the Effectiveness of SARS-CoV-2 Vaccines

Lewnard, Joseph A.a,b,c; Patel, Manish M.d; Jewell, Nicholas P.e,f; Verani, Jennifer R.d; Kobayashi, Miwakod; Tenforde, Mark W.d; Dean, Natalie E.g; Cowling, Benjamin J.h; Lopman, Benjamin A.i

Author Information
Epidemiology 32(4):p 508-517, July 2021. | DOI: 10.1097/EDE.0000000000001366


Observational studies of the effectiveness of vaccines to prevent COVID-19 are needed to inform real-world use. Such studies are now underway amid the ongoing rollout of SARS-CoV-2 vaccines globally. Although traditional case-control and test-negative design studies feature prominently among strategies used to assess vaccine effectiveness, such studies may encounter important threats to validity. Here, we review the theoretical basis for estimation of vaccine direct effects under traditional case-control and test-negative design frameworks, addressing specific natural history parameters of SARS-CoV-2 infection and COVID-19 relevant to these designs. Bias may be introduced by misclassification of cases and controls, particularly when clinical case criteria include common, nonspecific indicators of COVID-19. When using diagnostic assays with high analytical sensitivity for SARS-CoV-2 detection, individuals testing positive may be counted as cases even if their symptoms are due to other causes. The traditional case-control design may be particularly prone to confounding due to associations of vaccination with healthcare-seeking behavior or risk of infection. The test-negative design reduces but may not eliminate this confounding, for instance, if individuals who receive vaccination seek care or testing for less-severe illness. These circumstances indicate the two study designs cannot be applied naively to datasets gathered through public health surveillance or administrative sources. We suggest practical strategies to reduce bias in vaccine effectiveness estimates at the study design and analysis stages.

Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

You can read the full text of this article if you:

Access through Ovid